Literature DB >> 7868129

An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution.

A K Daly1, J B Leathart, S J London, J R Idle.   

Abstract

The cytochrome P450 CYP2D6 is a polymorphic enzyme, for which 5%-10% of Caucasians (poor metabolizers) lack activity. The majority of mutations giving rise to the deficiency have now been identified but some individuals show anomalous phenotype-genotype relationships when screened for the common mutant alleles. We have sequenced all nine exons and intron-exon boundaries in a subject who was phenotypically a poor metabolizer but genotypically heterozygous when screened for the common alleles. A single base-pair deletion (T1795) was detected in exon 3 and a base substitution (G2064A) resulting in an amino acid substitution (G212E) in exon 4. The deletion results in premature termination of translation and a truncated protein. In a group of 50 white Americans, the allele frequency for the new mutant allele was 0.01. The new allele explains some cases of anomalous genotype/phenotype relationships for CYP2D6.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7868129     DOI: 10.1007/bf00225204

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  10 in total

1.  Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.

Authors:  M L Dahl; I Johansson; M P Palmertz; M Ingelman-Sundberg; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1992-01       Impact factor: 6.875

2.  Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.

Authors:  M Kagimoto; M Heim; K Kagimoto; T Zeugin; U A Meyer
Journal:  J Biol Chem       Date:  1990-10-05       Impact factor: 5.157

3.  Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.

Authors:  A K Daly; M Armstrong; S C Monkman; M E Idle; J R Idle
Journal:  Pharmacogenetics       Date:  1991-10

4.  The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.

Authors:  S Kimura; M Umeno; R C Skoda; U A Meyer; F J Gonzalez
Journal:  Am J Hum Genet       Date:  1989-12       Impact factor: 11.025

5.  Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.

Authors:  W E Evans; M V Relling
Journal:  Pharmacogenetics       Date:  1991-12

6.  Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.

Authors:  F Broly; A Gaedigk; M Heim; M Eichelbaum; K Morike; U A Meyer
Journal:  DNA Cell Biol       Date:  1991-10       Impact factor: 3.311

7.  Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.

Authors:  H Yokota; S Tamura; H Furuya; S Kimura; M Watanabe; I Kanazawa; I Kondo; F J Gonzalez
Journal:  Pharmacogenetics       Date:  1993-10

Review 8.  Metabolic polymorphisms.

Authors:  A K Daly; S Cholerton; W Gregory; J R Idle
Journal:  Pharmacol Ther       Date:  1993 Feb-Mar       Impact factor: 12.310

9.  The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population.

Authors:  M Armstrong; K Fairbrother; J R Idle; A K Daly
Journal:  Pharmacogenetics       Date:  1994-04

10.  Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6.

Authors:  S L Wang; J D Huang; M D Lai; B H Liu; M L Lai
Journal:  Clin Pharmacol Ther       Date:  1993-04       Impact factor: 6.875

  10 in total
  10 in total

Review 1.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 2.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

3.  An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine.

Authors:  D Marez; M Legrand; N Sabbagh; J M Lo-Guidice; P Boone; F Broly
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

4.  Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

Authors:  C Sachse; J Brockmöller; S Bauer; I Roots
Journal:  Am J Hum Genet       Date:  1997-02       Impact factor: 11.025

5.  Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers.

Authors:  Rasmus Steen Pedersen; Per Damkier; Kim Brøsen
Journal:  Eur J Clin Pharmacol       Date:  2006-06-09       Impact factor: 2.953

6.  CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.

Authors:  Jean E Abraham; Mel J Maranian; Kristy E Driver; Radka Platte; Bolot Kalmyrzaev; Caroline Baynes; Craig Luccarini; Mitul Shah; Susan Ingle; David Greenberg; Helena M Earl; Alison M Dunning; Paul D P Pharoah; Carlos Caldas
Journal:  Breast Cancer Res       Date:  2010-08-23       Impact factor: 6.466

Review 7.  Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions.

Authors:  J-D Maréchal; C A Kemp; G C K Roberts; M J I Paine; C R Wolf; M J Sutcliffe
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

8.  A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.

Authors:  M R Shiran; J Chowdry; A Rostami-Hodjegan; S W Ellis; M S Lennard; M Z Iqbal; O Lagundoye; N Seivewright; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

9.  CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort.

Authors:  Concetta Dagostino; Massimo Allegri; Valerio Napolioni; Simona D'Agnelli; Elena Bignami; Antonio Mutti; Ron Hn van Schaik
Journal:  Pharmgenomics Pers Med       Date:  2018-10-24

10.  Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors.

Authors: 
Journal:  Genet Med       Date:  2007-12       Impact factor: 8.822

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.